GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Other Events

ME Staff 8-k
-
0

GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Other Events
Item 9.01 Other Events.

On August 7, 2017, Gemphire Therapeutics Inc. (“Gemphire”) issued a press release regarding its ROYAL-1 Phase 2b clinical trial of gemcabene in hypercholesterolemic patients.

A copy of the press release is filed as Exhibit99.1 to this Current Report on Form8-K and incorporated herein by reference.Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

Description

99.1

Press Release dated August 7, 2017.


Gemphire Therapeutics Inc. Exhibit
EX-99.1 2 gemp-20170807ex99123a86f.htm EX-99.1 Gemp_8-K_Ex_991 Exhibit 99.1           Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients   Gemcabene met the primary endpoint and demonstrated a statistically significant lowering in LDL-C   Company to host conference call at 8:00 am ET,…
To view the full exhibit click here

About GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP)

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.